Enthea, a benefits provider for psychedelic-assisted therapy, has closed on $2 million in seed funding — the first of two tranches, CEO Sherry Rais tells Axios.
Why it matters: Unlike most psychedelic-assisted therapy efforts that focus on drug development, Enthea is following a more established playbook as a third-party administrator (TPA) to administer less conventional benefits.
